CONTROL BIONICS LIMITED — Capital/Financing Update 2024

May 12, 2024

Market Announcement

==> picture [33 x 50] intentionally omitted <==

13 May 2024

==> picture [451 x 5] intentionally omitted <==

Control Bionics Limited (ASX: CBL) – Trading Halt

Description

The securities of Control Bionics Limited (‘CBL’) will be placed in trading halt at the request of CBL, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 15 May 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

13 May 2024 ASX Limited

10732280v1

==> picture [145 x 45] intentionally omitted <==

13 May 2024

Ms Zufishan Anjum Adviser, Listings Compliance ASX Limited 20 Bridge Street Sydney NSW 2000

By email: tradinghaltssydney@asx.com.au

Dear Ms Anjun

REQUEST FOR TRADING HALT: CBL LTD (ASX: CBL)

Pursuant to Listing Rule 17.1, Control Bionics Limited ( CBL ) requests that its securities be placed in a trading halt with effect from the commencement of trading today.

In accordance with ASX Listing Rule 17.1, and in support of its request, CBL advises that:

• a) it requests a trading halt pending an announcement in relation to a capital raising;

• b) it requests that the trading halt remain in place until the earlier of:

• (i) the time CBL makes an announcement to the market about the results of the proposed capital raising; and

• (ii) (ii) the commencement of trading on 15 May 2024; and

• c) it is not aware of any reason why the trading halt should not be granted, or of any other information necessary to inform the market about the trading halt.

Your faithfully

Brett Crowley Company Secretary

About Control Bionics:

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics Limited

Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Victoria, 3121, Australia T: +61 3 9897 3576 W: www.controlbionics.com ABN: 45 115 465 462

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time.

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip ® . This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.

Investors and Media

Jeremy Steele – CEO and Managing Director jsteele@controlbionics.com

Brett Crowley - Company Secretary brettcrowley@controlbionics.com

Investor Relations:

Joe Durak Executive Director & Founder Lynx Advisors joe@lynxadvisors.com.au +61 414 465 582

For further information visit the website: https://www.controlbionics.com/